Abstract
The discovery of novel therapies for a disease often begins with identifying the cellular and biochemical target whose malfunction is implicated in the initiation or progression of the disease. Because abnormally high or low activity of proteins (receptors, enzymes, or transporters) or of the genes that code for these proteins is the underlying cause of most diseases, therapeutic intervention requires modulation of the target protein or gene activity by chemical agents. Identifying the chemical agents that can modulate activities of specific proteins or genes with a high degree of selectivity and potency through rational design or high throughput screening with combinatorial libraries has become a less daunting task in the past two decades. This is because most proteins can be readily expressed, isolated, and structurally characterized, their functional activity can be assessed using in vitro systems, and vast numbers of compounds can be synthesized using combinatorial approaches as potential modulators of their expression or functional activity. However, it is important to recognize that the therapeutic efficacy of these agents in humans can only by achieved if sufficiently high concentration of these compounds can be attained and maintained at the target site. This requires that the compound has appropriate physicochemical properties so that (i) it can be absorbed effectively from the site of administration (e.g. gastrointestinal tract for orally administered compounds), (ii) it escapes extensive metabolism in the liver and other extrahepatic tissues, (iii) it is distributed sufficiently in the target tissue, and (iv) it is not excreted too rapidly via the renal or the hepatobiliary clearance mechanisms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amidon and Sadee 1999. Membrane Transporters as Drug Targets. New York, NY: Kluver Academic/Plenum Publishers, 1999
Anderson JM and Van Itallie CM. Tight Junctions and the Molecular Basis for Regulation of Paracellular Permeability. Am J Physiol 269; 1995:G467–G475
Ansede JH and Thakker DR. In Vitro High Throughput Screening for Inhibition and Metabolic Stability of Compounds Towards Cytochrome P450-mediated Oxidative Metabolism. J. Pharm. Sci 93; 2004:239–255
Artursson P. Correlation Between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells. Biochem Biophys Res Commun 1991; 175:880–885
Ballard P, Arundel PA, Leahy DE, and Rowland M. Prediction of In Vivo Tissue Distribution from In Vitro Data. 2. Influence of Albumin Diffusion from Tissue Pieces During an In Vitro Incubation on Estimated Tissue-to-unbound Plasma Partition Coefficients (kpu). Pharm Res 2003a; 20:857–863
Ballard P, Leahy DE, and Rowland M. Prediction of In Vivo Tissue Distribution from In Vitro Data. 3. Correlation between In Vitro and In Vivo Tissue Distribution of a Homologous Series of Nine 5-n-Alkyl-5-ethyl Barbituric Acids. Pharm Res 2003b; 20:864–872
Borchardt RT, Smith PL, and Wilson G. Models for Assessing Drug Absorption and Metabolism. New York, NY: Plenum Press; 1996
Caldwell GW, Ritchie DM, Masucci JA, Hageman W, and Yan Z. The New Preclinical Paradigm: Compound Optimization in Early and Late Phase Drug Discovery. Curr Top Med Chem 2001; 1:353–366
Cohen LH, Remley MJ, Raunig D, and Vaz AD. In Vitro Drug Interactions of Cytochrome P450: An Evaluation of Fluorogenic to Conventional Substrates. Drug Metab Dispos 2003; 31: 1005–1015
Ekins S. Past, Present, and Future Applications of Precision-cut Liver Slices for In Vitro Xenobiotic Metabolism. Drug Metab Rev. 1996; 28:591–623
Evans DC, Watt AP, Nicoll-Griffith DA, and Bailie TA. Drug Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. Chem Res Toxicol 2004; 17:3–16
Fromm MF. P-glycoprotein: A Defense Mechanism Limiting Oral Bioavailability and CNS Accumulation of Drugs. Int J Clin Pharmacol Ther 2000; 38:69–74
Hidalgo IJ, Raub TJ, and Borchardt RT. Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability. Gatroenterology 1989; 96:736–749
Honkakoski P and Negishi M. Regulation of Cytochrome P450 (CYP) Genes by Nuclear Receptors. Biochem J 2000; 347:321–337
Houston JB and Calile DJ. Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices. Drug Met Rev 1997; 29:891–922
Iwatsubo T, Hirota N, Ooie T, Suzuki H, and Sugiyama Y. Prediction of In Vivo Drug Disposition from In Vitro Data Based on Physiological Pharmacokinetics. Biopharm and Drug Disp 1996; 17:273–310
Kalvass JC and Maurer. TS. Influence of Nonspecific Brain and Plasma Binding on CNS Exposure: Implications for Rational Drug Discovery. Biopharm Drug Dispos 2002; 23: 327–338.
Kennedy T. Managing the Drug Discovery/Development Interface. Drug Discov Today 1997; 2:436–444
Kerns EH and Li D. Pharmaceutical Profiling in Drug Discovery. Drug Discov Today 2003; 8:316–323
Leahy DE and Rowland M. Prediction of In Vivo Tissue Distribution from In Vitro Data 1. Experiments with Markers of Aqueous Spaces. Pharm Res 2000; 17:660–663
LeCluyse EL. Human Hepatocyte Culture Systems for the In Vitro Evaluation of Cytochrome P450 Expression and Regulation. Eur J Pharm Sci 2001; 13:343–368
LeCluyse EL, Bullock PL, Parkinson A, and Hochman JH. Cultured Rat Hepatocytes. In: Borchardt RT, Smith PL, and Wilson G. Model for Assessing Drug Absorption and Metabolism. New York, NY: Plenum Press; 1996. 121–159
Lin JH and Lu AYH. Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes. Ann Rev Pharmacol Toxicol 2001; 41:535–567
Lin JH and Yamazaki M. Role of P-glycoprotein in Pharmacokinetics: Clinical Implications. Clin Pharmacokinet 2003; 42:59–98
Lee K and Thakker DR. Saturable Transport of H2-Antagonists Ranitidine and Famotidine across Caco-2 Cell Monolayers. J Pharm Sci; 1999:88:680–687
Liu X, Brouwer, KL, Gan LS, Brouwer KR, Stieger B, Meier PJ, Audus KL, and LeCluyse EL. Partial Maintenance of Taurocholate Uptake by Adult Rat Hepatocytes Cultured in a Collagen Sandwich Configuration. Pharm Res 1998; 15:1533–1539
Liu X, LeCluyse EL, Brouwer KR, Gan LS, LeMasters JJ, Stieger B, Meier PJ, and Brouwer KL. Biliary Excretion in Primary Rat Hepatocytes Cultured in a Collagen-Sandwich Configuration. Am J Physiol 1999a; 277:G12–G21
Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KL. Correlation of Biliary Excretion in Sandwich-Cultured Rat Hepatocytes and In Vivo in Rats. Drug Metab Dispos 1999b; 27:637–644
Low LK. Metabolic Changes of Drugs and Related Organic Compounds. In:Delgado JN and Remers WA. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry (Tenth Edition). Philadelphia, PA: Lippincott Co.; 1998. 43–122
Maurel P. The Use of Human Hepatocytes in Primary Culture and Other In Vitro Systems to Investigate Drug Metabolism in Man. Adv Drug Delivery Rev 1996; 22:105–132
Moore JT and Kliewer SA. Use of the Nuclear Receptor PXR to Predict Drug Interactions. Toxicology 2000; 153:1–10
Obach RC, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre, F, Rance DJ, and Wastall P. The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data. J Pharmacol Exp Ther 1997; 283:46–58
Parkinson A. Biotransformation of Xenobiotics. In: Klaassen CD. Casarett & Doull’s Toxicology (Fifth Edition) New York, NY: McGraw-Hill; 1996. 113–186
Polli JW and Serabjit-Singh CJ. In Vitro Cell-based Assays for Estimating the Effects of Efflux Transporters on Cell Permeation. In: Borchardt RT, Kerns EH, Lipinski, CA, Thakker, DR, and Wang B. Pharmaceutical Profiling in Drug Discovery for Lead Selection. Arlington, VA: AAPS Press; 2004. 235–256
Powell DW. Barrier Function of Epithelia. Am J Physiol 241; 1981: G275–G288.
Rendic S and Di Carlo FJ. Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors. Drug Metab Rev 1997; 29:413–580
Rowland M. Physiological Pharmacokinetic Models and Ineranimal Species Scaling. Pharmacol Ther 1985; 29:49–68
Savas U, Griffin KJ, and Johnson EF. Molecular Mechanisms of Cytochrome P450 Induction by Xenobiotics: An Expanded Role of Nuclear Hormone Receptors. Mol Pharmacol 1999; 56:851–857
Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP. Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414–423
Silva JM and Nicoll-Griffith DA. In Vitro Models for Studying Induction of Cytochrome P450 Enzymes. In: Rodrigues AD. Drug — Drug Interaction. New York, NY: Marcel Dekker; 2002. 189–216
Smith P. In Vitro Models for Selection of Development Candidate: Advanced Drug Delivery Reviews. 1997; 23 (No. 1–3).
Thiel-Demby VE, Tippin TK, Humphreys JE, Serabjit-Singh CJ, and Polli, JW. In Vitro Absorption and Secretory Quotients: Practical Criteria Derived from a Study of 331 Compounds to Assess for the Impact of P-glycoprotein-mediated Efflux on Drug Candidates. J Pharm Sci 2004; 93:2567–2572
Troutman MD and Thakker DR. The Efflux Ratio Cannot Assess P-glycoprotein-mediated Attenuation of Absorptive and Secretory Transport Across Caco-2 Cell Monolayers. Pharm Res 2003a; 20:1200–1209
Troutman MD and Thakker DR. Rhodamine 123 Requires Carrier-Mediated Influx for its Activity as a P-glycoprotein Substrate in Caco-2 Cells. Pharm Res 2003b; 20:1192–1199
Troutman MD and Thakker DR. Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-glycoprotein in Cell Culture Models of Intestinal Epithelium. Pharm Res 2003c; 20:1210–1226
Walsh J. Metabolic Activation — Role in Toxicity and Idiosyncratic Reactions. In: Borchardt RT, Kerns EH, Hegeman J, Thakker DR, and Stevens JL. Optimization of Drug-Like Properties During Lead Optimization. Arlington, VA: Springer/AAPS Press; 2005. 49–80.
Wang H and LeCluyse EL. Role of Orphan Nuclear Receptors in the Regulation of Drug Metabolizing Enzymes. Clin Pharmacokinet 2003; 42:1331–1357
Ward PD, Tippin TK, and Thakker DR. Enhancing Paracellular Permeability by Modulating Epithelial Tight Junctions. Pharm Sci Tech Today 2000; 3:346–358
Waterbeemd HVD, Smith DA, Beaumont K, and Walker DK. Property-based Design: Optimization of Drug Absorption and Pharmacokinetics. J Med Chem 2001a; 15:1313–1333
Waterbeemd HVD, Smith DA, and Jones BC. Lipophilicity in PK design: Methyl, Ethyl, Futile. J Comput Aid Mol Design 2001b; 15:273–286.
Weinstein K, Kardos, P, Strab R, and Hidalgo, IJ. Cultured Epithelial Cell Assays Used to Estimate Intestinal Absorption Potential. In: Borchardt RT, Kerns EH, Lipinski, CA, Thakker, DR, and Wang B. Pharmaceutical Profiling in Drug Discovery for Lead Selection. Arlington, VA: AAPS Press; 2004. 217–234
Zamek-Gliszczynski MJ and Brouwer KLR. In Vitro Models for Estimating Hepatobiliary Clearance. In: Borchardt RT, Kerns EH, Lipinski, CA, Thakker, DR, and Wang B. Pharmaceutical Profiling in Drug Discovery for Lead Selection. Arlington, VA: AAPS Press; 2004. 259–292
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Thakker, D.R. (2006). Strategic Use of Preclinical Pharmacokinetic Studies and In Vitro Models in Optimizing ADME Properties of Lead Compounds. In: Borchardt, R.T., Kerns, E.H., Hageman, M.J., Thakker, D.R., Stevens, J.L. (eds) Optimizing the “Drug-Like” Properties of Leads in Drug Discovery. Biotechnology: Pharmaceutical Aspects, vol IV. Springer, New York, NY. https://doi.org/10.1007/978-0-387-44961-6_1
Download citation
DOI: https://doi.org/10.1007/978-0-387-44961-6_1
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-34056-2
Online ISBN: 978-0-387-44961-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)